Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc., in collaboration with Asher Biotherapeutics, is initiating a Phase 1b clinical study titled ‘A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311).’ The study aims to assess the safety, tolerability, and pharmacokinetics of the drug combination, with a focus on determining the maximum tolerated dose of AB248 when used with Tarlatamab. This research is significant as it explores potential new treatment avenues for extensive stage small cell lung cancer, a condition with limited therapeutic options.
The intervention involves two experimental drugs, Tarlatamab and AB248, both administered via intravenous infusion. The primary goal is to evaluate their combined safety and effectiveness in treating the targeted cancer stage.
The study design is interventional, non-randomized, and follows a sequential intervention model without masking, focusing primarily on treatment. This straightforward approach aims to identify the optimal dosing strategy for the drug combination.
Key timeline milestones include an estimated start date of August 29, 2025, with the study currently not yet recruiting participants. The last update was submitted on August 19, 2025, indicating ongoing preparations for the study’s commencement.
From a market perspective, this study could influence Amgen’s stock performance positively if successful, as it may lead to new treatment options in the oncology sector. Investors should watch for updates, as the study’s progress could affect market dynamics, especially in comparison to competitors in the cancer treatment industry.
The study is ongoing, with further details available on the ClinicalTrials portal.